Vaxxinity Inc (VAXX)
OTHER OTC:VAXX
Want to see VAXX full AI Analyst Report?
VAXX Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume1.04K
Average Volume (3M)5.29K
Market Cap
$2.11M
Enterprise Value$10.25M
Total Cash (Recent Filing)$30.39M
Total Debt (Recent Filing)$15.17M
Price to Earnings (P/E)―
Beta319.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding126,784,680
10 Day Avg. Volume3,116
30 Day Avg. Volume5,294
Financial Highlights & Ratios
PEG Ratio18.90
Price to Book (P/B)8.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap4.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.27
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative Vaccine PlatformVaxxinity's innovative platform for developing vaccines positions it well in the biotechnology sector, potentially transforming treatment landscapes for chronic diseases.
Strategic CollaborationsStrategic collaborations and partnerships can enhance Vaxxinity's market reach and provide essential funding, aiding in the development and commercialization of its products.
Cash PositionA strong cash position provides Vaxxinity with a liquidity cushion, allowing it to navigate financial challenges and invest in R&D for future growth.
Bears Say
High Financial LeverageHigh financial leverage can strain Vaxxinity's financial stability, increasing risk and potentially limiting its ability to invest in growth opportunities.
Lack Of Revenue GrowthThe absence of revenue growth and ongoing losses highlight challenges in monetizing products, which could hinder long-term sustainability and investor confidence.
Negative Cash FlowsNegative cash flows indicate operational inefficiencies and financial strain, potentially impacting Vaxxinity's ability to fund its R&D and operational activities.
Vaxxinity Inc News
VAXX FAQ
What was Vaxxinity Inc’s price range in the past 12 months?
Vaxxinity Inc lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Vaxxinity Inc’s market cap?
Vaxxinity Inc’s market cap is $2.11M.
When is Vaxxinity Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Vaxxinity Inc’s earnings last quarter?
Currently, no data Available
Is Vaxxinity Inc overvalued?
According to Wall Street analysts Vaxxinity Inc’s price is currently Overvalued.
Does Vaxxinity Inc pay dividends?
Vaxxinity Inc does not currently pay dividends.
What is Vaxxinity Inc’s EPS estimate?
Vaxxinity Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxxinity Inc have?
Vaxxinity Inc has 126,784,680 shares outstanding.
What happened to Vaxxinity Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxxinity Inc?
Currently, no hedge funds are holding shares in VAXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.02% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---